On the 21st July 2022, Pacific Edge announced that it had substantially completed a commercial agreement with Te Whatu Ora – Southern for the use of its non-invasive Cxbladder genomic biomarker tests.

After advising the market that the signing of the Contract has been delayed on the 22nd September 2022, Pacific Edge can now confirm the signed executed agreement has been received.

View the original release - 21 July 2022.